An anti‐IL‐1β antibody has been approved by the FDA for the treatment of autoimmune disorders such as systemic juvenile idiopathic arthritis and adult‐onset Still's disease, and combining anti‐IL‐1β and anti‐PD‐1/L1 antibodies potentiates treatment effects in clinical applications. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.